Une cause originale d’insuffisance rénale aiguë au cours du myélome multiple : néphrite interstitielle aiguë induite par le lénalidomide

IF 0.7 4区医学 Q4 UROLOGY & NEPHROLOGY Nephrologie & Therapeutique Pub Date : 2022-11-01 DOI:10.1016/j.nephro.2022.03.004

Aboubacar Sidiki Fofana , Christophe Bouaka , Ghassan Alchahin , Simona Dorina Boncila , Magara Samaké , Seydou Sy , Hamadoun Yattara , Saharé Fongoro , Julia Torrents , Rolande Cohen Valensi , Delphine Haussaire

{"title":"Une cause originale d’insuffisance rénale aiguë au cours du myélome multiple : néphrite interstitielle aiguë induite par le lénalidomide","authors":"Aboubacar Sidiki Fofana , Christophe Bouaka , Ghassan Alchahin , Simona Dorina Boncila , Magara Samaké , Seydou Sy , Hamadoun Yattara , Saharé Fongoro , Julia Torrents , Rolande Cohen Valensi , Delphine Haussaire","doi":"10.1016/j.nephro.2022.03.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Lenalidomide is an immunomodulatory drug widely used in the treatment of multiple myeloma. Several cases of nephrotoxicity have been reported, but few have been documented histologically.</p></div><div><h3>Case presentation</h3><p>We report a case of acute interstitial nephritis to lenalidomide in a 62-year-old patient with multiple myeloma after administration of the second course of chemotherapy according to the protocol combining bortezomib, lenalidomide and dexamethasone. The outcome was quickly favorable after stopping lenalidomide, with corticosteroid therapy.</p></div><div><h3>Conclusion</h3><p>Lenalidomide may be responsible for acute interstitial nephritis. When acute kidney injury occurs in myeloma, the nephrotoxicity of therapeutic agents should be considered in addition to the common causes of kidney failure. The chronology of events and the histological data are essential and guide the specific management.</p></div>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"18 6","pages":"Pages 565-569"},"PeriodicalIF":0.7000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologie & Therapeutique","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1769725522000876","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction

Lenalidomide is an immunomodulatory drug widely used in the treatment of multiple myeloma. Several cases of nephrotoxicity have been reported, but few have been documented histologically.

Case presentation

We report a case of acute interstitial nephritis to lenalidomide in a 62-year-old patient with multiple myeloma after administration of the second course of chemotherapy according to the protocol combining bortezomib, lenalidomide and dexamethasone. The outcome was quickly favorable after stopping lenalidomide, with corticosteroid therapy.

Conclusion

Lenalidomide may be responsible for acute interstitial nephritis. When acute kidney injury occurs in myeloma, the nephrotoxicity of therapeutic agents should be considered in addition to the common causes of kidney failure. The chronology of events and the histological data are essential and guide the specific management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多发性骨髓瘤急性肾功能不全的原始原因:lenalidomide引起的急性间质性肾炎

来那度胺是一种广泛用于多发性骨髓瘤治疗的免疫调节药物。一些肾毒性的病例已被报道，但很少有组织学记录。我们报告了一个62岁的多发性骨髓瘤患者，根据硼替佐米、来那度胺和地塞米松联合化疗方案，在第二期化疗后出现急性间质性肾炎。在停用来那度胺并辅以皮质类固醇治疗后，结果迅速好转。结论来那度胺可能与急性间质性肾炎有关。当骨髓瘤发生急性肾损伤时，除了肾衰竭的常见原因外，还应考虑治疗药物的肾毒性。事件的年表和组织学数据是必要的，并指导具体的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nephrologie & Therapeutique 医学-泌尿学与肾脏学

CiteScore

0.80

自引率

14.30%

发文量

485

审稿时长

11.9 weeks

期刊介绍： Organe d''expression de la Société de Néphrologie, de la Société Francophone de Dialyse et de la Société de Néphrologie Pédiatrique, Néphrologie et Thérapeutique a pour vocation de publier des textes en français dans le domaine de la Néphrologie, qu''il s''agisse d''actualisation des connaissances, de recommandations de bonne pratique clinique, de publications originales, ou d''informations sur la vie des trois sociétés fondatrices. La variété des thèmes abordés reflète la richesse de la Néphrologie, qu''il s''agisse d''aspects fondamentaux issus de la physiologie, de l''immunologie, de l''anatomo-pathologie, ou de la génétique, ou de sujets de néphrologie clinique, notamment ceux en rapport avec les thérapeutiques néphrologiques, transplantation, hémodialyse et dialyse péritonéale.

期刊最新文献

Posters Posters commentés Communications orales [Biological parameters for assessment and monitoring anemia in hemodialysis patients]. [Arguments for the use of cardiac biomarkers in hemodialysis: natriuretic peptides and troponins].